Winzerlaer Str. 2
49 3641 508 180
Full Time Employees: 44
|Dr. Niels C. Riedemann M.D., Ph.D.||Co-Founder, CEO & Exec. Director||N/A||N/A||1973|
|Prof. Renfeng Guo M.D.||Co-Founder, Chief Scientific Officer & Exec. Director||N/A||N/A||1970|
|Dr. Thomas Taapken Ph.D.||Chief Financial Officer||N/A||N/A||1965|
|Mr. Christian Schmid||VP and Head of Legal Affairs & Gen. Counsel||N/A||N/A||N/A|
|Ms. Nicole Bertsch||Sr. Director & Head of HR||N/A||N/A||N/A|
|Dr. Maria Habel PH.D.||Head of Preclinical R&D||N/A||N/A||1982|
|Ms. Evelyn Roth-Geissler Ph.D.||VP & Head of Clinical Operations||N/A||N/A||N/A|
|Dr. Bruce P. Burnett Ph.D.||VP & Head of Medical Affairs||N/A||N/A||N/A|
|Mr. Kafi Boaten||Sr. Director and Head of Supply & Clinical Trial Supplies||N/A||N/A||N/A|
|Mr. Peter Hurt Ph.D.||Sr. Director and Head of Drug Safety & Pharmacovigiliance||N/A||N/A||N/A|
InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage. The company also develops INF904, an oral, small molecule drug candidate for the chronic inflammatory and autoimmune diseases; and IFX002 that is in pre-clinical development stage for the treatment of chronic inflammation and autoimmune diseases. It has co-development agreement with Beijing Defengrei Biotechnology Co. Ltd.; and clinical trial collaboration and supply agreement with Merck & Co. Inc. The company was formerly known as Fireman B.V. and changed its name to InflaRx N.V. in 2017. InflaRx N.V. was founded in 2007 and is headquartered in Jena, Germany.
InflaRx N.V.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.